IPAMORELIN

So What Does This Actually Mean?

Plain English summary — no PhD required

Ipamorelin is a growth hormone secretagogue — a compound that stimulates the release of growth hormone from the pituitary gland. Unlike CJC-1295 (which mimics the 'go' signal from the hypothalamus), Ipamorelin mimics a different signal called ghrelin, often called the 'hunger hormone.' But Ipamorelin is engineered to trigger GH release without most of ghrelin's other effects.

What It Does

Ipamorelin binds to the GHS-R1a receptor on pituitary cells — the same receptor that ghrelin uses — and triggers a pulse of growth hormone release. What makes it notable in research is its selectivity: it stimulates GH release without significantly raising cortisol, prolactin, or ACTH levels, which are common side effects of other GH secretagogues. This clean selectivity profile makes it a useful research tool for studying GH biology in isolation.

Why It Matters

In research, Ipamorelin is often paired with CJC-1295 because they work through complementary pathways — CJC-1295 amplifies the GH pulse, while Ipamorelin triggers it. Together, they're studied as a way to produce a more robust GH response than either compound alone. The combination is one of the most discussed stacks in GH axis research.

The Bottom Line

Ipamorelin's standout quality is its selectivity — it's one of the cleanest GH secretagogues studied to date, with minimal effects on other hormonal axes. It's a research-only compound and is prohibited by WADA. Purgo Labs supplies it in research-grade lyophilized form for laboratory use only.

Overview

What is Ipamorelin?

Ipamorelin (NNC-26-0161) is a synthetic pentapeptide and highly selective agonist of the growth hormone secretagogue receptor (GHS-R), also known as the ghrelin receptor. Developed by Novo Nordisk in the 1990s, ipamorelin was designed to stimulate growth hormone release with greater selectivity and a cleaner hormonal profile than earlier growth hormone-releasing peptides (GHRPs) such as GHRP-2 and GHRP-6.

The defining characteristic of ipamorelin in the research literature is its selectivity: unlike GHRP-2 and GHRP-6, which significantly elevate cortisol, prolactin, and ACTH alongside GH, ipamorelin stimulates GH release with minimal effect on these other hormones. This selectivity has made it a preferred research tool for studying the GH/IGF-1 axis in isolation.

Key Takeaways

• Ipamorelin is a pentapeptide GH secretagogue that activates the GHS-R1a (ghrelin) receptor in the pituitary to trigger pulsatile GH release

• Exceptional selectivity: stimulates GH release without significantly raising cortisol, prolactin, or ACTH — a key advantage over older GH secretagogues like GHRP-6

• Complementary mechanism to CJC-1295: Ipamorelin triggers the GH pulse (GHRP pathway) while CJC-1295 amplifies it (GHRH pathway) — the most studied GH axis research stack

• Half-life ~2 hours; typically studied at 100–300 mcg per injection in animal models

• WADA-prohibited research compound; not approved for human use

Composition

Molecular Composition

Amino Acid Sequence

Aib-His-D-2-Nal-D-Phe-Lys-NH2

Ipamorelin is a pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, where Aib is alpha-aminoisobutyric acid and D-2-Nal is D-2-naphthylalanine. These non-natural amino acid residues are critical to the compound's pharmacological profile: Aib at the N-terminus confers resistance to aminopeptidase degradation, while the D-amino acids at positions 3 and 4 prevent cleavage by endopeptidases and enhance GHS-R binding affinity.

The molecular weight is 711.85 Daltons, making ipamorelin one of the smallest GHS-R agonists. The C-terminal amide group is required for full receptor binding activity.

Mechanism of Action

How Does It Work?

!

Ipamorelin triggers growth hormone release by activating the ghrelin receptor in the pituitary, producing clean GH pulses without raising cortisol or prolactin.

Ipamorelin acts as a selective agonist at the growth hormone secretagogue receptor (GHS-R1a), a G-protein coupled receptor expressed primarily on somatotroph cells in the anterior pituitary gland and on neurons in the hypothalamus. GHS-R1a activation by ipamorelin initiates a Gαq/11-mediated signaling cascade, increasing intracellular inositol trisphosphate (IP3) and diacylglycerol (DAG) levels, which in turn elevate intracellular calcium concentrations and activate protein kinase C (PKC).

This signaling cascade triggers the exocytosis of GH-containing secretory granules from somatotroph cells, producing a rapid, pulsatile GH release. Ipamorelin also attenuates the inhibitory effects of somatostatin on GH secretion, effectively amplifying the GH pulse. The resulting GH elevation stimulates hepatic IGF-1 production, which mediates the downstream anabolic effects.

Ipamorelin Mechanism of Action — Simplified signaling pathway diagram. For research reference only.

"Ipamorelin exhibits a distinct pharmacological profile, selectively stimulating growth hormone release through GHS-R agonism while maintaining endocrine specificity, positioning it as a valuable tool for elucidating the intricacies of the somatotropic axis." — Raun et al., European Journal of Endocrinology, 1998